Success Metrics

Clinical Success Rate
93.9%

Based on 31 completed trials

Completion Rate
94%(31/33)
Active Trials
1(3%)
Results Posted
19%(6 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_2
9
24%
Ph phase_3
9
24%
Ph not_applicable
3
8%
Ph phase_1
5
13%
Ph phase_4
9
24%

Phase Distribution

5

Early Stage

9

Mid Stage

18

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
5(14.3%)
Phase 2Efficacy & side effects
9(25.7%)
Phase 3Large-scale testing
9(25.7%)
Phase 4Post-market surveillance
9(25.7%)
N/ANon-phased studies
3(8.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.2%

31 of 34 finished

Non-Completion Rate

8.8%

3 ended early

Currently Active

1

trials recruiting

Total Trials

38

all time

Status Distribution
Active(1)
Completed(31)
Terminated(3)
Other(3)

Detailed Status

Completed31
unknown3
Terminated2
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
38
Active
1
Success Rate
93.9%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (14.3%)
Phase 29 (25.7%)
Phase 39 (25.7%)
Phase 49 (25.7%)
N/A3 (8.6%)

Trials by Status

unknown38%
active_not_recruiting13%
terminated25%
completed3182%
withdrawn13%

Recent Activity

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more
NCT07046156

Treatment of Overactive Bladder With Anticholinergic Agents

Active Not Recruiting
NCT00688688Phase 3

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Completed
NCT00689104Phase 3

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Completed
NCT01604928Phase 2

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

Completed
NCT00966004Phase 3

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Completed
NCT03602508

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed
NCT00523068Phase 4

Pharmacological vs Surgical Treatment for Mixed Incontinence

Withdrawn
NCT05946902Phase 4

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Unknown
NCT00481728Phase 1

Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.

Completed
NCT03572231

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed
NCT00730535Phase 4

Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients

Completed
NCT02256943Phase 4

Genetic Determinants of Amitriptyline Efficiency for Pain Treatment

Completed
NCT02256956Phase 4

Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II

Completed
NCT00323635Phase 4

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

Terminated
NCT02599311Phase 3

the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery

Unknown
NCT00564226Phase 2

SSR240600C Treatment in Women With Overactive Bladder

Completed
NCT01179828Phase 3

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

Completed
NCT01356355Phase 2

Study of Herbmed Plus in Ureteral Stent Discomfort

Completed
NCT01036035Phase 1

Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects

Completed
NCT01530243Phase 2

The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

Completed

Drug Details

Intervention Type
DRUG
Total Trials
38